MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'exforge'. Sat, 03 Sep 2011 03:00:55 +0100 http://www.medworm.com/index.php?rid=4159502&cid=t_184266_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FcpByhX1L0_8%2F This may give new meaning to the notion of playing ball. Hoping to entice doctors to prescribe more meds, Novartis assembled a star-studded line up of athletes to pitch its drugs at dinners between 2006 and 2009. Among them: baseball Hall of Famers Bob Gibson and Johnny Bench, New York Giants quarterback Eli Manning and former New York Knicks forward Walt ‘Clyde’ Frazier. As you might imagine, the athletes gave short speeches, answered questions about their careers, signed memorabilia and posed for photos. Novartis reps later brought the photos when they called on the docs. In all, the drugmaker paid $3.6 million in fees to 150 top former and current sports figures - from $8,000 to $35,000 an appearance, according to The Washington Times. Interestingly, the events were used to... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4159502 Fri, 12 Nov 2010 14:18:49 +0100 4159502 http://www.medworm.com/index.php?rid=4018441&cid=t_184266_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FaK3IEXLaIa8%2F Another week, another drugmaker agrees to settle off-label marketing charges brought by the federal government. This time, Novartis will pay $422.5 million for illegally promoting its Trileptal epilepsy med for unapproved uses, such as bipolar disorder and neuropathic pain, along with five other drugs - Diovan, Zelnorm, Sandostatin, Exforge and Tekturna. The fine includes roughly $237 million to settle four lawsuits brought by whistleblowers, while $185 million goes toward criminal penalties. One of the lawsuits was filed by Jeremy Garrity, a former cardiovascular sales rep, who worked for Novartis between 2002 and 2008 before being fired (you can read it here, and you can read the settlement here. Oh, and this is the guilty plea). This is the latest in a stream of settlements involving bi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4018441 Thu, 30 Sep 2010 17:26:16 +0100 4018441 http://www.medworm.com/index.php?rid=2381352&cid=t_184266_111_f&fid=36048&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FAHeartyLife%2F%7E3%2FBvtZH9occb4%2F We already have a 2-in-1 high blood pressure/high cholesterol drug on the market, called Caduet, but now the FDA has approved a 3 in 1, called Exforge HCT. The new pill is a combination of a calcium channel blocker, angiotensin receptor blocker and diuretic - so-called water pills. Here is the press release issued by the manufacturer, Novartis: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill EAST HANOVER, N.J., April 30 /PRNewswire/ — The US Food and Drug Administration (FDA) has approved Exforge HCT (amlodipine, valsartan, hydrochlorothiazide), the only blood pressure (BP) treatment to combine three medications in a single pill. Exforge HCT combines the number one prescribed calcium channel blocker, angiotensin rece... A Hearty Life blogs http://www.medworm.com/rss/comments.php?id=2381352 Fri, 01 May 2009 09:00:26 +0100 2381352 http://www.medworm.com/index.php?rid=1466102&cid=t_184266_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F296681277%2Fexforge_effective_for_african_americans.html A drug called Exforge, by pharmaceutical Novartis Ag, could help to significantly reduce high blood pressure in black patients. Using this drug reduces systolic blood pressure more than just amlodipine. Exforge is a combination of both amlodipine and Diovan, two leading medications in the field for treating blood pressure. Results with Exforge were seen after only two weeks of taking the medication. Studying black patients is of great concern for they are not only the most likely ethnic group to have high blood pressure, but also less likely to achieve blood pressure control even when receiving treatment. "The large blood pressure reductions seen in this trial were experienced by severe patients who have the most difficulty getting their blood pressure to healthy levels," sa... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=1466102 Thu, 22 May 2008 17:00:53 +0100 1466102